Telix Pharmaceuticals (TLX) to Release Quarterly Earnings on Thursday

Telix Pharmaceuticals (NASDAQ:TLX) is anticipated to release its H2 2025 results after the market closes on Thursday, February 19th. Analysts expect Telix Pharmaceuticals to post earnings of $0.0493 per share and revenue of $421.5040 million for the quarter. Individuals can find conference call details on the company’s upcoming H2 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 5:30 PM ET.

Telix Pharmaceuticals Trading Up 1.7%

TLX stock opened at $6.54 on Tuesday. Telix Pharmaceuticals has a 1 year low of $6.34 and a 1 year high of $30.36. The stock has a 50-day simple moving average of $7.72 and a 200-day simple moving average of $9.39.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of TLX. Rhumbline Advisers increased its holdings in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the second quarter worth $213,000. Private Advisor Group LLC grew its holdings in Telix Pharmaceuticals by 67.3% in the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after purchasing an additional 16,945 shares during the period. JPMorgan Chase & Co. bought a new stake in Telix Pharmaceuticals in the third quarter valued at $243,000. Finally, Jane Street Group LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter valued at about $564,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.